(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/094567 A1

(51) International Patent Classification:
A61K 31/53 (2006.01) *A61K 31/704* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2021/072065

(22) International Filing Date:
28 October 2021 (28.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/106,643	28 October 2020 (28.10.2020)	US
63/106,692	28 October 2020 (28.10.2020)	US
63/111,281	09 November 2020 (09.11.2020)	US
63/262,145	06 October 2021 (06.10.2021)	US

(71) Applicant: **IKENA ONCOLOGY, INC.** [US/US]; 645 Summer Street, Suite 101, Boston, Massachusetts 02210 (US).

(72) Inventors: **CASTRO, Alfredo C.**; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, BOSTON, Massachusetts 02210 (US). **ZHANG, Xiaoyan Michelle**; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, BOSTON, Massachusetts 02210 (US). **SAGER, Jason**; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, BOSTON, Massachusetts 02210 (US). **MCGOVERN, Karen J.**; c/o Ikena Oncology, Inc., 645 Summer Street, Suite 101, BOSTON, Massachusetts 02210 (US).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: COMBINATION OF AN AHR INHIBITOR WITH A PDX INHIBITOR OR DOXORUBICINE

(57) Abstract: The present invention provides AHR inhibitors, and methods of use thereof.

WO 2022/094567 A1